Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).

FDA expands Juxtapid approval for pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia to reduce plasma LDL-C levels.

Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. We conducted a randomized, ...

Red blood cells are the most abundant cells in the body. It has long been known that when red blood cells break down or anemia occurs due to bleeding, the hormone erythropoietin (EPO) increases, ...

Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular events in initially healthy women. Elevated plasma lipoprotein(a) is a ...

Lipoprotein (a) is a low-density lipoprotein that transports cholesterol in the blood. The lipoprotein (a) test — or Lp(a) test — determines the level of this lipoprotein in the blood, and its results ...

People who are at higher risk for heart disease also seem more likely to develop dementia. And research led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has ...

Certain supplements are said to boost your metabolism and act as natural fat burners. But do they work? Find out what the research says about five supplements for metabolism.